Clinical Trials on BRAFV600E Melanoma Patients in United States

Total 3134 results

Mayo Clinic
National Cancer Institute (NCI)

Completed

Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Viral Therapy in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

Recurrent Melanoma | Stage IV Melanoma

United States
Providence Health & Services
Merck Sharp & Dohme LLC; Eisai Inc.

Recruiting

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Melanoma, Uveal

United States
University of Colorado, Denver
National Comprehensive Cancer Network; Taiho Oncology, Inc.

Recruiting

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

Malignant Melanoma

United States
Providence Health & Services
Prometheus Laboratories

Active, not recruiting

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. (SBRT/IL-2)

Metastatic Melanoma

United States
Masonic Cancer Center, University of Minnesota

Completed

Radiation and Combination Immunotherapy for Melanoma

Metastatic Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Metastatic Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Melanoma (Skin)

United States
OHSU Knight Cancer Institute

Completed

Vascular Response to Brachytherapy Using Functional OCT

Uveal Melanoma

United States
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Completed

IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

Malignant Melanoma

United States
F. Stephen Hodi, MD
MedImmune LLC

Completed

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Metastatic Melanoma

United States
Ludwig Institute for Cancer Research
Cancer Research Institute (CRI)

Completed

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Malignant Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Celgene
Prologue Research International

Completed

Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Malignant Melanoma

United States
Providence Health & Services
Providence Cancer Center, Earle A. Chiles Research Institute; Galectin Therapeutics...

Completed

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Milton S. Hershey Medical Center

Completed

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

Malignant Melanoma

United States
University of Arizona

Terminated

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

Malignant Melanoma

United States
Western Regional Medical Center

Terminated

Interleukin-2 in Metastatic Melanoma

Melanoma Metastatic

United States
New England Retina Associates

Completed

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

Choroidal Melanoma

United States
New England Retina Associates
Genentech, Inc.

Completed

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Choroidal Melanoma

United States
University of California, Davis

Completed

Comparison of Video-Based Versus Written Patient Education on Melanoma

Melanoma | Malignant Melanoma

United States
University of Massachusetts, Worcester

Completed

Intratumoral Injection Of Alpha-Gal Glycosphingolipids

Metastatic Melanoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye

Intraocular Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

Melanoma (Skin)

United States
New England Retina Associates

Completed

Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma

Choroidal Melanoma

United States
M.D. Anderson Cancer Center
Aventis Pharmaceuticals

Completed

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

Metastatic Melanoma

United States
Molecular Insight Pharmaceuticals, Inc.

Terminated

Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma

Metastatic Melanoma

United States
Mannkind Corporation

Terminated

Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage III Melanoma | Extraocular Extension Melanoma

United States
Gradalis, Inc.

Completed

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

Melanoma | Malignant Melanoma | Melanoma Recurrent

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Recurrent Melanoma | Stage IV Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Terminated

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Pfizer; Beth Israel Deaconess Medical Center

Completed

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United States
Yale University
National Cancer Institute (NCI)

Completed

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Eisai Inc.

Terminated

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Unresectable Stage III Melanoma | Wild Type BRAF Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States

Clinical Trials on BRAFV600E Melanoma Patients in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations